none28siOBJECTIVE: In this prospective population-based registry study on ALS survival, we investigated the role of riluzole treatment, together with other clinical factors, on the prognosis in incident ALS cases in Emilia Romagna Region (ERR), Italy. METHODS: A registry for ALS has been collecting all incident cases in ERR since 2009. Detailed clinical data from all patients diagnosed with ALS between 1.1.2009 and 31.12.2014 have been analyzed for this study, with last follow up date set at 31.12.2015. RESULTS: During the 6 years of the study, there were 681 incident cases with a median tracheostomy-free survival of 40 months (95% CI 36-44) from onset and of 26 months (95% CI 24-30) from diagnosis; 573 patients (84.14%) were treated w...
Background: Amyotrophic lateral sclerosis (ALS) is a progressive and usually fatal neurodegenerative...
This study reports the results of a long-term cost-effectiveness analysis of riluzole in the treatme...
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motorne...
OBJECTIVE: In this prospective population-based registry study on ALS survival, we investigated the...
The prognostic role of riluzole, enteral nutrition (EN), non-invasive ventilation (NIV) and interdis...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...
Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with spo...
The aim of this multicenter, retrospective study is to investigate the role of clinical characterist...
Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in...
Background: This analysis describes the use of riluzole in amyotrophic lateral sclerosis (ALS) indiv...
Background: Amyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS...
Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS...
Ana Paróla,1 Fátima da Silva Mousinho de Palhares Falcão,1,2 Helena Farinha,1 A...
<div><p>Objective</p><p>To determine the prognostic factors associated with survival in amyotrophic ...
Background: Amyotrophic lateral sclerosis (ALS) is a progressive and usually fatal neurodegenerative...
This study reports the results of a long-term cost-effectiveness analysis of riluzole in the treatme...
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motorne...
OBJECTIVE: In this prospective population-based registry study on ALS survival, we investigated the...
The prognostic role of riluzole, enteral nutrition (EN), non-invasive ventilation (NIV) and interdis...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...
Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with spo...
The aim of this multicenter, retrospective study is to investigate the role of clinical characterist...
Purpose: Riluzole is indicated to prolong life or delay the institution of mechanical ventilation in...
Background: This analysis describes the use of riluzole in amyotrophic lateral sclerosis (ALS) indiv...
Background: Amyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS...
Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS...
Ana Paróla,1 Fátima da Silva Mousinho de Palhares Falcão,1,2 Helena Farinha,1 A...
<div><p>Objective</p><p>To determine the prognostic factors associated with survival in amyotrophic ...
Background: Amyotrophic lateral sclerosis (ALS) is a progressive and usually fatal neurodegenerative...
This study reports the results of a long-term cost-effectiveness analysis of riluzole in the treatme...
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motorne...